Cargando…
Early antibody responses associated with survival in COVID19 patients
Neutralizing antibodies to the SARS CoV-2 spike proteins have been issued Emergency Use Authorizations and are a likely mechanism of vaccines to prevent COVID-19. However, benefit of treatment with monoclonal antibodies has only been observed in clinical trials in outpatients with mild to moderate C...
Autores principales: | Zhou, Zhao-Hua, Dharmarajan, Sai, Lehtimaki, Mari, Kirshner, Susan L., Kozlowski, Steven |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8321400/ https://www.ncbi.nlm.nih.gov/pubmed/34280244 http://dx.doi.org/10.1371/journal.ppat.1009766 |
Ejemplares similares
-
Evaluation of association of anti-PEG antibodies with anaphylaxis after mRNA COVID-19 vaccination
por: Zhou, Zhao-Hua, et al.
Publicado: (2023) -
A novel murine in vivo model for acute hereditary angioedema attacks
por: Bupp, Sujata, et al.
Publicado: (2021) -
Early non-neutralizing, afucosylated antibody responses are associated with COVID-19 severity
por: Chakraborty, Saborni, et al.
Publicado: (2022) -
A case of coronavirus disease 2019 messenger RNA vaccine tolerance and immune response despite presence of anti-polyethylene glycol antibodies
por: Corey, Kristen B., et al.
Publicado: (2022) -
Early T cell and binding antibody responses are associated with COVID-19 RNA vaccine efficacy onset
por: Kalimuddin, Shirin, et al.
Publicado: (2021)